Clinical Trial Search

Primary: Cohort 1: Change in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) Score From Baseline at 24 Weeks as Compared to Placebo — -4.0; -7.0; -5.4; -6.9 Unit on a…

Primary: Beats Per Minute Change With VR — -2; -6.25; -8.8; -6.25 Beats per minute

Primary: Area Under the Concentration-time Curve From Time Zero to Infinity [Extrapolated] (AUC0-inf): ALG-097558 in Part A and Part C, Dabigatran (Total) in Plasma in Part B…

Primary: Feasibility of Obtaining Baseline Clinical and PRO Data Capture From 200 Consented Patients. — 196 Participants

Primary: Number of Patients Who Receive All Reimbursements and Who Complete Follow-up Surveys (Overall Feasibility of Intervention) — 33; 0 Participants

Primary: Change in Body Weight (%) — -12.2; -2.2 Percentage change in body weight — p=<0.0001

Primary: The Percentage of Participants Who Had at Least 1 Indeterminate Tissue or Unexpected Fluorescent End of Surgery (EOS) Tissue Where Gleolan-induced PpIX Fluorescence…

Primary: Phobia Symptom Severity — 2.80; 3.18; 1.51; 1.55 units on a scale

Primary: Positive & Negative Symptom Scale Total (PANSSt) — 56.77; 54.24; 52.23; 49.29 score on a scale — p=0.004

Primary: Acute Postoperative Pain (With NRS ) — 3.5; 3; 4; 4 NRS score — p=0.365

Primary: Progression Free Survival at 15 Weeks. — 17; 18 Participants

Primary: ROBoT-r Task Performance Score (During Stimulation) — 73.19; 75.33; 76.64; 77.62 score on a scale (0-100) — p=0.049

Primary: Frailty — 3.63; 3.48 score on a scale

Primary: Safety Measurement — 0; 0; 0; 0 Adverse events

Primary: Overall Response Rate (ORR) — 50 percentage of participants